Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up-Reference-Cited by-同舟云学术

Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up

Published:2017-09-22 Issue:4 Volume:177 Page:924-935
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Lee H.Y.¹,Walsh S.A.²,Creamer D.²

Affiliation:

1. Department of Dermatology; Singapore General Hospital; Singapore

2. Department of Dermatology; King's College Hospital; London U.K.

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjd.15360/fullpdf

Reference109 articles.

1. Severe cutaneous adverse reactions to drugs;Roujeau;N Engl J Med,1994

2. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme;Bastuji-Garin;Arch Dermatol,1993

3. Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France, 1981-1985;Roujeau;Arch Dermatol,1990

4. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry;Rzany;J Clin Epidemiol,1996

5. Toxic epidermal necrolysis. Clinical findings and prognosis in 87 patients;Revuz;Arch Dermatol,1987

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ocular involvement in Steven-Johnson syndrome/toxic epidermal necrolysis: recent insights into pathophysiology, biomarkers, and therapeutic strategies;Current Opinion in Ophthalmology;2024-08-13

2. Post-marketing safety concern of PI3K inhibitors in the cancer therapies: an 8-year disproportionality analysis from the FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-07-31

3. Advances in Clinical Pharmacogenomics and Prevention of Severe Cutaneous Adverse Drug Reactions in the Era of Precision Medicine;Personalized Medicine - New Perspectives [Working Title];2024-07-17

4. High risk and low prevalence diseases: Stevens Johnson syndrome and toxic epidermal necrolysis;The American Journal of Emergency Medicine;2024-07

5. Trastuzumab‐induced toxic epidermal necrolysis in a Her‐2‐positive metastatic breast cancer patient—A rare case report;Clinical Case Reports;2024-06-23